Northern Trust Corp Buys 145,205 Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX)

Northern Trust Corp increased its stake in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX) by 30.8% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 616,891 shares of the company’s stock after acquiring an additional 145,205 shares during the period. Northern Trust Corp owned about 1.34% of Pacira BioSciences worth $11,622,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also bought and sold shares of the company. Hennion & Walsh Asset Management Inc. raised its stake in Pacira BioSciences by 18.1% in the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 56,385 shares of the company’s stock valued at $1,062,000 after buying an additional 8,636 shares during the period. Nisa Investment Advisors LLC raised its stake in Pacira BioSciences by 495.3% in the fourth quarter. Nisa Investment Advisors LLC now owns 3,304 shares of the company’s stock valued at $62,000 after buying an additional 2,749 shares during the period. Gagnon Securities LLC raised its stake in Pacira BioSciences by 4.8% in the fourth quarter. Gagnon Securities LLC now owns 321,743 shares of the company’s stock valued at $6,062,000 after buying an additional 14,800 shares during the period. China Universal Asset Management Co. Ltd. raised its stake in Pacira BioSciences by 10.3% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 9,790 shares of the company’s stock valued at $184,000 after buying an additional 918 shares during the period. Finally, Caitlin John LLC raised its stake in Pacira BioSciences by 1,850.0% in the fourth quarter. Caitlin John LLC now owns 1,872 shares of the company’s stock valued at $35,000 after buying an additional 1,776 shares during the period. Institutional investors own 99.73% of the company’s stock.

Pacira BioSciences Stock Up 1.0%

NASDAQ PCRX opened at $25.86 on Friday. The business has a fifty day moving average price of $24.88 and a two-hundred day moving average price of $22.37. The company has a debt-to-equity ratio of 0.51, a current ratio of 2.25 and a quick ratio of 1.89. Pacira BioSciences, Inc. has a fifty-two week low of $11.16 and a fifty-two week high of $31.67. The stock has a market capitalization of $1.20 billion, a PE ratio of -12.74 and a beta of 0.56.

Analyst Ratings Changes

Several research firms have issued reports on PCRX. Barclays upped their price objective on Pacira BioSciences from $17.00 to $24.00 and gave the company an “overweight” rating in a research note on Friday, February 28th. HC Wainwright upped their target price on Pacira BioSciences from $48.00 to $65.00 and gave the company a “buy” rating in a research report on Tuesday, April 8th. Needham & Company LLC reduced their price target on Pacira BioSciences from $32.00 to $30.00 and set a “buy” rating on the stock in a research report on Friday, May 9th. Finally, Truist Financial raised Pacira BioSciences from a “sell” rating to a “hold” rating and increased their price target for the stock from $8.00 to $25.00 in a research report on Thursday, January 30th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $26.44.

Pacira BioSciences Profile

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.